{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:03:13Z","timestamp":1792159393205,"version":"4.4.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.oret.2025.07.019","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T02:45:00Z","timestamp":1754448300000},"page":"142-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Risk of Sight-Threatening Diabetic Retinopathy with Glucagon-Like Peptide-1 Receptor Agonist Use in Routine Clinical Practice"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2666-3828","authenticated-orcid":false,"given":"Andrew J.","family":"Barkmeier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6841-7706","authenticated-orcid":false,"given":"Yihong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavya Sindhu","family":"Swarna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3671-3622","authenticated-orcid":false,"given":"Jeph","family":"Herrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Polley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3252-5026","authenticated-orcid":false,"given":"Guillermo E.","family":"Umpierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9295-3225","authenticated-orcid":false,"given":"Rodolfo J.","family":"Galindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9218-3320","authenticated-orcid":false,"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3664-127X","authenticated-orcid":false,"given":"Mindy M.","family":"Mickelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2289-3183","authenticated-orcid":false,"given":"Rozalina G.","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2025.07.019_bib1","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"suppl 1","key":"10.1016\/j.oret.2025.07.019_bib2","first-page":"S181","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"10.1016\/j.oret.2025.07.019_bib3","first-page":"S207","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.oret.2025.07.019_bib4","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jama.2024.18219","article-title":"GLP-1 medication use for type 2 diabetes has soared","volume":"332","author":"Hegland","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.oret.2025.07.019_bib5","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oret.2025.07.019_bib6","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oret.2025.07.019_bib7","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/archopht.116.7.874","article-title":"Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial","volume":"116","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2025.07.019_bib8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2337\/db14-0930","article-title":"Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT\/EDIC","volume":"64","author":"Lachin","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.oret.2025.07.019_bib9","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/dom.13538","article-title":"Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review","volume":"21","author":"Bain","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.oret.2025.07.019_bib10","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2337\/dc20-1815","article-title":"HbA1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression","volume":"44","author":"Bethel","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.oret.2025.07.019_bib11","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.survophthal.2023.07.002","article-title":"GLP-1 receptor agonists and diabetic retinopathy: a meta-analysis of randomized clinical trials","volume":"68","author":"Kapoor","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.oret.2025.07.019_bib12","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oret.2025.07.019_bib13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oret.2025.07.019_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.oret.2025.07.019_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100852","article-title":"Derivation of an annualized claims-based major adverse cardiovascular event estimator in type 2 diabetes","volume":"3","author":"McCoy","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.oret.2025.07.019_bib16","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.oret.2025.07.019_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.oret.2025.07.019_bib18","article-title":"STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies","volume":"372","author":"Wang","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.oret.2025.07.019_bib19","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1377\/hlthaff.2014.0038","article-title":"Optum Labs: building a novel node in the learning health care system","volume":"33","author":"Wallace","year":"2014","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.oret.2025.07.019_bib21","author":"Polley"},{"key":"10.1016\/j.oret.2025.07.019_bib22","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.oret.2025.07.019_bib23","doi-asserted-by":"crossref","DOI":"10.2202\/1544-6115.1309","article-title":"Super learner","volume":"6","author":"van der Laan","year":"2007","journal-title":"Stat Appl Genet Mol Biol"},{"key":"10.1016\/j.oret.2025.07.019_bib24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/EDE.0000000000000627","article-title":"Matching weights to simultaneously compare three treatment groups: comparison to three-way matching","volume":"28","author":"Yoshida","year":"2017","journal-title":"Epidemiology"},{"key":"10.1016\/j.oret.2025.07.019_bib25","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.oret.2025.07.019_bib26","series-title":"Application of Time-to-Event Methods in the Assessment of Safety in Clinical Trials. Biostatistics Series","year":"2009"},{"key":"10.1016\/j.oret.2025.07.019_bib27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"10.1016\/j.oret.2025.07.019_bib28","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/sim.9681","article-title":"A comparison of different methods to adjust survival curves for confounders","volume":"42","author":"Denz","year":"2023","journal-title":"Stat Med"},{"key":"10.1016\/j.oret.2025.07.019_bib29","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/sim.7297","article-title":"Causal inference in survival analysis using pseudo-observations","volume":"36","author":"Andersen","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.oret.2025.07.019_bib30","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1214\/20-EJS1740","article-title":"Correcting an estimator of a multivariate monotone function with isotonic regression","volume":"14","author":"Westling","year":"2020","journal-title":"Electron J Stat"},{"key":"10.1016\/j.oret.2025.07.019_bib31","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.oret.2024.05.003","article-title":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, and sulfonylureas for sight-threatening diabetic retinopathy","volume":"8","author":"Barkmeier","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.07.019_bib32","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00417-023-06273-0","article-title":"SGLT2 inhibitors and diabetic retinopathy progression","volume":"262","author":"Nadelmann","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2025.07.019_bib33","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/09286586.2024.2399764","article-title":"Glucagon-like peptide-1 receptor agonists are not associated with an increased risk of progressing to vision-threatening diabetic retinopathy","volume":"32","author":"Tauqeer","year":"2025","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.oret.2025.07.019_bib34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ajo.2024.04.010","article-title":"Impact of GLP-1 agonists and SGLT-2 inhibitors on diabetic retinopathy progression: an aggregated electronic health record data study","volume":"265","author":"Wai","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2025.07.019_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2024.103099","article-title":"Glucagon-like peptide-1 receptor agonists and risk of sight-threatening retinopathy in Taiwanese population: a propensity based cohort study","volume":"18","author":"Yen","year":"2024","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.oret.2025.07.019_bib36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1016\/j.oret.2025.07.019_bib37","first-page":"S103","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes-2019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.oret.2025.07.019_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2024-004431","article-title":"Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA","volume":"12","author":"King","year":"2024","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.oret.2025.07.019_bib39","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/14740338.2024.2354885","article-title":"Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile","volume":"23","author":"Scheen","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.oret.2025.07.019_bib40","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/87551225241266773","article-title":"Utilization of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitors at the Veterans Health Administration","volume":"40","author":"Krishnan","year":"2024","journal-title":"J Pharm Technol"},{"key":"10.1016\/j.oret.2025.07.019_bib41","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.oret.2025.07.019_bib42","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/db15-0443","article-title":"Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes","volume":"65","author":"Hern\u00e1ndez","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.oret.2025.07.019_bib43","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3803\/EnM.2017.32.3.316","article-title":"Effects of incretin-based therapies on diabetic microvascular complications","volume":"32","author":"Kang","year":"2017","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.oret.2025.07.019_bib44","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11892-018-1011-7","article-title":"Molecular mechanisms underlying the cardiovascular benefits of SGLT2i and GLP-1RA","volume":"18","author":"Khat","year":"2018","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.oret.2025.07.019_bib45","article-title":"Neuroprotective role of GLP-1 analog for retinal ganglion cells via PINK1\/parkin-mediated mitophagy in diabetic retinopathy","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.oret.2025.07.019_bib46","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025003550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025003550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T07:28:59Z","timestamp":1779866939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653025003550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2468653025003550"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2025.07.019","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Sight-Threatening Diabetic Retinopathy with Glucagon-Like Peptide-1 Receptor Agonist Use in Routine Clinical Practice","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2025.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}